Historically, biotech companies have been forced to build their own software tools in-house. This is an expensive, time-consuming challenge that distracts from the work that matters: developing and commercializing core IP. Thankfully, emerging vertical software tools are giving biotechs a better alternative: buy software that is extensible, and adapt it. Read more - https://blog.kaleidoscope.bio/why-biotechs-should-buy-more-of-their-software/ #biotech #biotechnology #biotechsoftware #buyvsbuild